The MEN2A oncogene encodes for a constitutive active member of the RET receptor tyrosine kinase family. Here, we report that MEN2A-RET activates Signal Transducer and Activator of Transcription 3 (STAT3) via two YxxV/Q STAT3 docking sites, Tyr752 and Tyr928. MEN2A-RET induces both Tyr705 and Ser727 phosphorylation of STAT3, and STAT3 serine phosphorylation is required for its maximal transcriptional activity. Stable NIH3T3 cell lines expressing both MEN2A-RET and STAT3a but not STAT3b, are characterized by enhanced proliferation and cyclin-D1 promoter activity, and enhanced growth in soft agar. These data indicate that malignant cell growth induced by MEN2A-RET involves its activation of STAT3. Oncogene (2001) 20, 5350 ± 5358.
Introduction
The RET proto-oncogene encodes for a member of the receptor family of tyrosine kinase (RTK) superfamily that plays a crucial role during the development of the enteric nervous system and the kidney (Takahashi and Cooper, 1987; Taraviras et al., 1999; Schuchardt et al., 1994; Takahashi et al., 1988) . Germline mutations at cysteine residues in the extracellular domain (cys609, 7611, 7618, 7620, 7630, and 7634) are responsible for the majority of multiple endocrine neoplasia type 2A (MEN2A) syndromes and familial medullary thyroid carcinoma (FMTC) (Ponder, 1999; DonisKeller et al., 1993; Mulligan et al., 1993) . MEN2A mutations induce a ligand-independent constitutive activation of RET which leads to abnormal cell growth, dierentiation defects and cellular transformation (Asai et al., 1995 (Asai et al., , 1996 Pasini et al., 1997; Santoro et al., 1995; Borrello et al., 1995) . Speci®cally, MEN2A is characterized by the association of medullary thyroid carcinoma (MTC), pheochromocytomas and hyperparathyroidism (DeLellis, 1995; Goodfellow and Wells, 1995) .
Although information on signal transduction downstream of the MEN2A mutated RET (MEN2A-RET) receptor is still limited, it has been demonstrated that several tyrosine residues are autophosphorylated in MEN2A-RET, including tyr905, tyr1015, tyr1062 and tyr1096 which serve as docking sites for Grb7/Grb10/ Grb14, phospholipase Cg, Shc/Enigma or FRS2, and Grb2, respectively (Borrello et al., 1996; Paratcha et al., 2001; Kurokawa et al., 2001; Durick et al., 1996; Liu et al., 1996; Pandey et al., 1996; Arighi et al., 1997; Lorenzo et al., 1997; Alberti et al., 1998) . Consequently, the Ras/ERK, JNK and PI-3K signal transduction pathways are activated by MEN2A-RET. However, the contribution of a sustained activation of these pathways to the MEN2A-RET induced proliferation and cellular transformation events are still unclear, although it has been demonstrated that activation of PI-3K contributes to the MEN2A-RET transforming capacity (Segoun-Cariou and Billaud, 2000) .
Signal Transducer and Activator of Transcription-3 (STAT3) belongs to a family of transcription factors that become activated by phosphorylation on a speci®c tyrosine residue in response to cytokines or growth factors (Darnell et al., 1994; Ihle, 1996; Schindler and Darnell, 1995) . Interferons, G-CSF and cytokines belonging to the IL-6 family induce STAT3 tyr705 phosphorylation via their subsequent receptors in a JAK kinase-dependent manner, whereas growth factors including EGF, PDGF and CSF1 can activate STAT3 through intrinsic receptor tyrosine kinase domains (Schindler and Darnell, 1995) . STAT3 tyr705 phosphorylation allows homodimerization as well as heterodimerization with other STAT family members, nuclear translocation and transcription activation (Heim et al., 1995; Stahl et al., 1995) . In addition to tyr705 phosphorylation, STAT3 is phosphorylated on ser727 which is a prerequisite for maximal STAT3 transactivation (Schuringa et al., 2000a; Wen et al., 1995) . Recently, a role of STAT3 in oncogenesis has been identi®ed in a number of studies. In various tumours, including leukaemias, lymphomas, breast cancers, and head and neck cancers, a constitutive activation of STAT3 has been observed in the absence of ligand stimulation Coer et al., 2000; Lin et al., 2000; Schuringa et al., 2000b; Song and Grandis, 2000) . In some cases, oncogenic tyrosine kinases like v-src activate STAT3 and induce cellular transformation in a STAT3-dependent manner (Bromberg et al., 1998; Cao et al., 1996; Turkson et al., 1998) . Furthermore, it has been demonstrated that STAT3 plays a key role in G1 to S phase cell-cycle transition through upregulation of cyclins D2, D3 and A, and cdc25A, and the concomitant downregulation of p21 and p27 (Fukada et al., 1998) . Also, Sinibaldi et al. (2000) have demonstrated that cyclin D1 is constitutively expressed in mouse ®broblasts stably transformed by v-Src in a STAT3-dependent manner. Thus, the constitutive STAT3 activation might aect proliferation and cell survival leading to a growth advantage over normal cells. Bromberg et al. (1999) demonstrated that a constitutive active STAT3 mutant, in which two cysteine residues within the C-terminal loop of the SH2 domain are substituted enabling constitutive STAT3 dimerization, induces cellular transformation and strongly upregulates the expression of cyclin-D1, c-myc and the anti-apoptotic protein Bcl-X L . These data suggest that a constitutive STAT3 activation might contribute by multiple mechanisms to the malignant phenotype of cells.
Here, we describe that MEN2A-RET can activate STAT3 via two YxxV/Q STAT3 docking sites, tyr752 and tyr928. Furthermore, we provide evidence that the malignant cell growth induced by MEN2A-RET involves its activation of STAT3.
Results

MEN2A-RET induces STAT3 transactivation and STAT3 tyr705 and ser727 phosphorylation
MEN2A mutations of the proto-oncogene Ret induce abnormal cell growth, dierentiation defects and cellular transformation, although little is known on the molecular mechanisms underlying these phenotypes. Since constitutive activation of STAT3 has also been reported to induce disturbed cell growth and cellular transformation, it was investigated whether STAT3 can be activated by MEN2A-RET. NIH3T3 and COS-7 cells were transiently transfected with an IRE-luciferase reporter containing two STAT3 binding sites together with expression vectors for MEN2A-RET and STAT3. As depicted in Figure 1a ,b, overexpression of both MEN2A-RET and STAT3 strongly enhanced IRE transactivation, while overexpression of STAT3 alone did not aect reporter activation. Since NIH3T3 cells express low levels of endogenous STAT3, overexpression of MEN2A-RET alone also slightly enhanced IRE transactivation ( Figure 1b) . As a control, a reporter with mutated IRE sites was used (Figure 1a,b) . Now, overexpression of both MEN2A-RET and STAT3 did not aect reporter activation. To study the phosphorylation status of STAT3, Western blotting experiments were performed demonstrating that overexpression of MEN2A-RET induced both STAT3 tyr705 and ser727 phosphorylation (Figure 1c ).
To further determine the role of STAT3 ser727 phosphorylation in STAT3 transactivation, STAT3b, which lacks the 55 C-terminal amino acid transactivation domain was overexpressed in NIH3T3 and COS-7 a b c Figure 1 MEN2A-RET induces STAT3 transactivation. COS-7 (a) and NIH3T3 (b) cells were transiently transfected with the IRE-luciferase or the IRE-mut-luciferase reporter together with expression vectors for MEN2A-RET, STAT3a, or STAT3b as indicated. pDM2-LacZ was co-transfected as an internal control to determine transfection eciencies and luciferase values were divided by LacZ values to give the corrected luciferase value (Corr. Luc. Value). Data represent three independent experiments, and each experiment was performed in triplicate. (c) COS-7 cells were transfected with expression vectors for MEN2A-RET and STAT3a as indicated, and total cell extracts were Western blotted using antibodies against phosphorylated STAT3 (tyr705 and ser727), STAT3 and MEN2A-RET cells together with MEN2A-RET and the IRE-luc reporter. As depicted in Figure 1a ,b, STAT3b did not signi®cantly mediate the MEN2A-RET induced transactivation of the IRE. Taken together, these data indicate that MEN2A-RET induces STAT3 transactivation, tyr705 and ser727 phosphorylation, and that the C-terminal transactivation domain of STAT3 is required for its maximal transactivation induced by MEN2A-RET.
MEN2A-RET induced STAT3 transactivation is independent of JAK2 and Src kinase activity, but involves the intrinsic tyrosine kinase domain of MEN2A-RET To determine whether the intrinsic tyrosine kinase domain of MEN2A-RET is involved in tyrosine phosphorylation of STAT3, or whether additional tyrosine kinases like Jaks or Src are involved, 3T3 cells were transiently transfected with the IRE-luc reporter and MEN2A-RET and STAT3 were overexpressed. Cells were pre-treated with chemical inhibitors against JAK2 (AG490), Src (PP2A) and tyrosine kinase receptors (AG1296). As depicted in Figure 2a , neither AG490 nor PP2A inhibited MEN2A-RET induced STAT3 transactivation. As a control, AG490 was used in a STAT3 transactivation experiment in IL-6 stimulated HepG2 cells, in which JAK2 kinase activity is required to mediate IL-6 induced STAT3 tyr705 phosphorylation (Heinrich et al., 1998) . IL-6 induced STAT3 transactivation was reduced from sixfold to 2.5-fold when cells were pretreated with the JAK2 inhibitor ( Figure 2b ). In contrast, MEN2A-RET induced STAT3 transactivation was reduced in a dose-dependent manner by the receptor tyrosine kinase inhibitor AG1296, suggesting that the intrinsic tyrosine kinase domain of MEN2A-RET is involved in MEN2A-RET induced STAT3 transactivation ( Figure 2b ). These results were further underscored by the observation that STAT3 tyr705 phosphorylation induced by MEN2A-RET was also reduced by treatment with AG1296 (data not shown).
The tyrosine residues 752 and 928 of MEN2A-RET are involved in STAT3 activation Tyrosine residues of cytokine receptors mediating STAT3 activation are located in conserved YxxQ sequences which serve as docking sites for STAT3 (Heinrich et al., 1998) . In the MEN2A-RET receptor, one such tyrosine residue is present at position 928 (YTTQ). To determine whether this residue indeed serves as a STAT3 docking site, tyrosine 928 was mutated into phenylalanine. As depicted in Figure 3a , mutation of tyr928 reduced STAT3 transactivation approximately 1.5-fold, indicating that other STAT3 docking sites must be present in MEN2A-RET as well. Since no other perfect YxxQ consensus sites were found in the sequence of MEN2A-RET, we decided to mutate the tyrosine residue 752, which is located in a Y(TT)V site and closely resembles the STAT3 docking site at position 928. Mutation of tyr752 reduced STAT3 transactivation approximately 2.2-fold, while the double mutant, in which both tyr752 and tyr928 were mutated into phenylalanines, did not signi®cantly induce STAT3 transactivation ( Figure 3a ). STAT3 tyr705 phosphorylation was reduced when the MEN2A-RET single mutants tyr752phe or tyr928phe were overexpressed, while no STAT3 tyr705 phosphorylation was observed in the presence of the MEN2A-RET double mutant ( Figure  3b ). Interestingly, when STAT3 was overexpressed in the absence of MEN2A-RET, basal STAT3 ser727 phosphorylation was observed, which was further enhanced by MEN2A-RET overexpression ( Figure 3b ). Overexpression of MEN2A-RET mutants reduced STAT3 ser727 phosphorylation to basal levels, suggesting that STAT3 tyr705 phosphorylation is a prerequisite for maximal MEN2A-RET induced STAT3 ser727 phosphorylation (Figure 3b) . Furthermore, MEN2A-RET and the MEN2A-RET double mutant were immunoprecipitated from transiently transfected COS-7 cells, and immunoprecipitates were blotted against STAT3, STAT3 eciently co-immunoprecipitated with MEN2A-RET, while association of STAT3 with the MEN2A-RET double mutants was severely impaired (Figure 3c ). The steady-state phosphorylation level of immunoprecipitated MEN2A-RET (Y752/928F) was not signi®cantly reduced as compared to MEN2A-RET when the immunoprecipitates were Western blotted using antibodies recognizing phosphorylated tyrosine residues (PY-99), suggesting that the introduced mutations did not aect the kinase function of MEN2A-RET (data not shown). Taken together, these data indicate that both tyr752 and tyr928 of the MEN2A-RET receptor serve as docking sites for STAT3. , and Y752/928F as indicated, and total cell lysates were Western blotted using antibodies against phosphorylated STAT3 (tyr705 and ser727), STAT3 and MEN2A-RET. (c) COS-7 cells were transiently transfected with MEN2A-RET, STAT3a, and/or the MEN2A-RET double mutant Y752/928F as indicated. MEN2A-RET was immunoprecipitated with antibodies against RET, and immunoprecipitates were blotted against STAT3. Blots were stripped and reprobed using antibodies against MEN2A-RET. As a control, the overexpression levels of STAT3 are shown stable cell lines nr. 1 and 24, while cells stably transfected with only the neomycin marker served as a control. As depicted in Figure 4c , cell lines nr. 1 and 24 were characterized by an enhanced proliferation rate as compared to control cells. Next, the MEN2A-RET stable cell line nr. 24 was used to generate double stable transfectants expressing either STAT3a or STAT3b. As a control, cells expressing both the neomycin and hygromycin markers were used. Double transfectants were tested for MEN2A-RET, STAT3a and STAT3b expression, as well as for STAT3 tyr705 phosphorylation. As depicted in Figure 5a , MEN2A-RET and STAT3 isoforms were properly expressed in the appropriate cell lines, while basal endogenous STAT3 expression was also detected in cell lines in which STAT3a was not stably transfected (a-STAT3, C20). Both STAT3a and STAT3b were phosphorylated on tyr705, con®rming that both STAT3 isoforms are activated by MEN2A-RET in the generated cell lines ( Figure  5a ). Furthermore, cells expressing both MEN2A-RET and STAT3a exhibited higher proliferation rates when compared to MEN2A-RET expressing clones, while in cells expressing both MEN2A-RET and STAT3b proliferation rates were reduced to the levels of control cells (Figure 5b ). These data indicate that MEN2A-RET enhances proliferation via STAT3, and that a full length STAT3 is required to mediate the MEN2A-RET induced proliferation. These observations correlated well with IRE and cyclin-D1 promoter activities (Figure 5c ). Finally, the transformed phenotype of the various cell lines was assessed by the capacity to grow in soft agar without anchorage. As shown in Figure  5d , cells expressing MEN2A-RET displayed a high number of colonies, which was strongly enhanced in cells expressing both MEN2A-RET and STAT3a. In contrast, cells expressing both MEN2A-RET and STAT3b displayed a reduced number of colonies, while control cells did not grow in soft agar ( Figure  5d ). Taken together, these data indicate that MEN2A-RET induced malignant cell growth is mediated via STAT3.
Discussion
Over the past few years, reports have accumulated providing evidence for the participation of constitutively activated STAT proteins in cellular transformation and the malignant progression of human cancers . Constitutive activated STAT3 has been found in several malignancies, including AML, multiple myeloma, head and neck cancers and many others Coer et al., 2000; Lin et al., 2000; Song and Grandis, 2000) . In some cases, oncogenic tyrosine kinases, including v-Src, vEyk and v-Ros, activate STAT3 in the absence of (a) Stable NIH3T3 cells expressing MEN2A-RET, MEN2A-RET and STAT3a or MEN2A-RET and STAT3b were generated as described in the Materials and methods section. As a control, cells only expressing the neomycin and hygromycin markers were used (neo/hyg). Lysates of each generated cell line were Western blotted using antibodies against MEN2A-RET; STAT3 (K15), which recognizes both STAT3a and STAT3b; STAT3 (C20), which only recognizes STAT3a; and STAT3 (tyr705-p), which only recognizes tyr705 phosphorylated STAT3. (b) Proliferation assay using the generated stable cell lines. (c) Stable cell lines were transiently transfected with the IRE-luc or cyclin-D1 luc reporter as indicated, and 48 h after transfection cells were harvested and lysates were assayed for luciferase and LacZ activities. (d) Soft agar assays were performed using the stable cell lines as indicated in the Materials and methods section. Representative phase contrast microscopy images (406) of colony formations are shown of control and MEN2A-RET/STAT3a cell lines, as well as the percentage of colonies that appeared after 21 days of incubation. The amount of colonies that appeared using the MEN2A-RET/STAT3a expressing clones was set at 100% extracellular ligand stimulation, (Bromberg et al., 1998; Cao et al., 1996; Turkson et al., 1998; Zong et al., 1996 Zong et al., , 1998 while in other cases a disturbed cytokine production in malignant cells has been identi®ed as the cause of disturbed STAT3 signaling (Schuringa et al., 2000b) . Here, we report that MEN2A, which encodes for a constitutive active member of the RET receptor tyrosine kinase family, activates STAT3 in the absence of GDNF stimulation. STAT3 is phosphorylated by MEN2A-RET on both the tyr705 and ser727 residues, enabling STAT3 target gene expression, which includes an upregulation of cyclin-D1 promoter activity. The MEN2A-RET induced proliferation and clonogenic growth in soft agar depends on the activation of STAT3, which can eectively be reduced by STAT3b as demonstrated by proliferation and soft agar assays. Both the tyrosine residues 752 and 928 of MEN2A-RET serve as docking sites for STAT3, since mutation of these residues into phenylalanine abrogated the MEN2A-RET induced STAT3 transactivation as well as STAT3 tyr705 phosphorylation. The tyr928 is located in a Y(TT)Q site, which is a conserved STAT3 docking site throughout many cytokine receptors known to activate STAT3, including the gp130 receptor (Heinrich et al., 1998) . The tyr752 is located in a Y(TT)V site, which has to our knowledge not yet been described as a STAT3 docking site. In immunoprecipitation studies, STAT3 eciently co-immunoprecipitated with MEN2A-RET, while STAT3 association with the MEN2A-RET double mutant Y752/928F was severely disturbed. However, some STAT3 association with MEN2A-RET (Y752/928F) was still observed, suggesting that other regions of MEN2A-RET might contribute to STAT3 recruitment as well. However, since neither STAT3 tyr705 phosphorylation nor STAT3 transactivation was induced by the MEN2A-RET tyr752/928phe double mutant, we conclude that these tyrosine residues are critical in mediating the recruitment and activation of STAT3.
Several synthetic inhibitors of tyrosine kinases were tested in order to identify the kinase that is involved in MEN2A-RET induced STAT3 tyr705 phosphorylation. We can exclude the possibility that JAK2 or Src are required, since AG490 and PP2A, which eectively inhibit JAK2 and Src kinase activity at the concentrations used, did not aect the MEN2A-RET induced STAT3 transactivation. We postulate that the intrinsic tyrosine kinase domain of MEN2A-RET is involved in phosphorylating STAT3 on tyr705, since the receptor tyrosine kinase inhibitor AG1296 both reduced MEN2A-RET induced STAT3 transactivation as well as STAT3 tyr705 phosphorylation (data not shown) in a dose-dependent manner. However, STAT3 transactivation levels were not completely reduced to basal levels in the presence of 40 mM AG1296. Whether the intrinsic tyrosine kinase domain is indeed sucient as well as required for inducing STAT3 tyr705 phosphorylation requires further experiments.
Mutations at cysteine residues in the extracellular domain of RET induce a ligand-independent activation of signal transduction cascades ®nally resulting in malignant transformation of endocrine tissues, including multiple neoplasia type 2 (MEN2A) (Asai et al., 1995; Donis-Keller et al., 1993; Mulligan et al., 1993; Ponder, 1999) . Autophosphorylation of several tyrosine residues in MEN2A-RET account for the observed disturbed signaling (Asai et al., 1995; Liu et al., 1996) . Speci®cally, phosphorylation of the tyrosine residue 1062 has been linked to activation of the PI-3K/AKT pathway and it has been demonstrated that activation of PI-3K contributes to the MEN2A-RET mediated cellular transformation, possibly by protecting cells from programmed cell death or potentiating G1 to S phase transition of the cell cycle (Segoun-Cariou and Billaud, 2000) . Now, we demonstrate that STAT3 is also an important downstream target of MEN2A-RET, and that MEN2A-RET induced proliferation and cellular transformation is signi®cantly enhanced by stable overexpression of STAT3 in NIH3T3 cells. In contrast, NIH3T3 cells expressing STAT3b are characterized by reduced proliferation rates and a less ecient growth in soft agar as compared to cells expressing MEN2A-RET alone due to the absence of the STAT3 transactivation domain. A disturbed activation of STAT3 has now been linked to a malignant phenotype of cells at the level of STAT3 target gene expression, including G1 to S phase cell cycle transition through an upregulation of cyclins D2, D3 and A, and cdc25A, as well as the concomitant downregulation of the cell cycle inhibitors p21 and p27 (Fukada et al., 1998) . Also, an upregulation of Bcl-X L has been demonstrated, indicating that activation of STAT3 might also contribute to anti-apoptotic events (Bromberg et al., 1999) . The data presented here provide a novel example of how STAT3 might contribute to the malignant progression of cancers in endocrine tissues that express the MEN2A-RET oncogene.
Materials and methods
Cell culture, reagents and antibodies COS-7 cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS, Integro B.V., Zaandam, The Netherlands) and NIH3T3 cells were grown in DMEM supplemented with 10% neural calf serum (NCS). Cells were stimulated with 25 ng/ml human recombinant IL-6 where indicated (generous gift from Dr SC Clark, Genetics Institute, Cambridge, USA). The inhibitors against JAK2 (AG490), Src (PP2A) and tyrosine kinase receptors (AG1296) were obtained from Calbiochem and used in ®nal concentrations of 15 mM, 20 nM and 10 ± 40 mM, respectively. Antibodies against MEN2A-RET (C19) and STAT3 (C20 and K15) were obtained from Santa Cruz and were used in dilutions of 1 : 4000. Antibodies against phosphorylated STAT3(Tyr705) and STAT3(Ser727) were obtained from New England Biolabs and used in a 1 : 1000 dilution. Antibodies against phosphorylated tyrosine residues (PY-99) were obtained from Santa Cruz and were used in a 1 : 1000 dilution.
Expression and reporter constructs
The pIRE-ti-LUC reporter was made by inserting a synthetic oligonucleotide (5'-ctagcaggTTTCCGGGAAAgcacagcttaggTTTCCGGGAAAgcac-3') containing two copies of the IL-6 response element (IRE) of the ICAM-1 promoter in the NheI site of the pGL3ti minimal promoter luciferase construct (Jonk et al., 1998) . Similar, pIREmut-ti-LUC was constructed by using a synthetic oligonucleotide (5'-ctagcaggTTAGCGGTCAAgcacagcttaggTTAGCGGTCAAgcac-3') with mutated IRE sites. Constructs were veri®ed by sequencing. The cyclin-D1 luciferase reporter containing the 7944 to +139 bp fragment of the human cyclin-D1 promoter was a gift from Dr P Pouyssegur (Centre de Biochimie, Faculte des Sciences, Parc Valrose, Nice, France) and described previously (Herber et al., 1994) . Furthermore, the following expression vectors were used: pSG5-STAT3a which expresses STAT3a from the SV40 promoter; pSG5-STAT3, which expresses a dominant negative isoform of STAT3 lacking the 55 C-terminal amino-acid residues (both were a gift from Dr R de Groot, Department of Pulmonary diseases AZU, Utrecht, The Netherlands) (Caldenhoven et al., 1996) ; and pCMV-MEN2A-RET(634), which expresses the Cys634 mutant of RET. The MEN2A-RET tyr752phe mutant was constructed by PCR using Pwo DNA polymerase (Roche, Mannheim, Germany) and the following primer pairs: RET forward, 5'-CAACAGGCAGGTGTGA-GTG-3' and RET tyr752phe reverse, 5'-ACCGTGGTGAA-CCCTGCTC-3'; and RET tyr752phe forward, 5'-GAG-CAGGGTTCACCACGGT-3' and RET reverse, 5'-GCCT-CAGAAGCCATAGAGC-3'. The two generated PCR fragments were then used in a new PCR reaction with the RET forward and RET reverse primers. This generated PCR fragment was digested with EcoRI and XbaI, and the EcoRI and XbaI fragment of pCMV-MEN2A-RET(634) was replaced with the EcoRI and XbaI PCR fragment. Similarly, the MEN2A-RET tyr928phe mutant was constructed by PCR using Pwo DNA polymerase and the following primer pairs: RET forward and RET tyr928phe reverse, 5'-GCG-TGGTGAAGATATGATC-3'; and RET tyr928phe forward, 5'-GATCATATCTTCACCACGC-3' and RET reverse. The two generated PCR fragments were then used in a new PCR reaction with the RET forward and RET reverse primers. This generated PCR fragment was digested with BglII and XbaI. pCMV-MEN2A-RET(634) was digested with XbaI and partially with BglII (only the BglII site in the MEN2A-RET cDNA was digested but not the BglII of the pCMV backbone) and the BglII and XbaI PCR fragment was inserted into the BglII and XbaI sites of pCMV-MEN2A-RET(634). The double mutant MEN2A-RET tyr752/928phe was constructed by replacing the BglII fragment of pCMV-MEN2A-RET tyr928phe with the BglII fragment of pCMV-MEN2A-RET-tyr752phe.
Transient transfections
Cells were seeded at 1610 5 cells per well in 6-well plates (Costar), and 24 h later cells were transfected with 10 mg plasmid DNA using the calcium phosphate co-precipitation method (Graham and Van der Eb, 1973) . Transfection mixtures consisted of a mixture of 2.5 mg luciferase reporter, 2.5 mg pDM2-LacZ as a control to determine transfection eciency, and 2.5 mg of expression plasmids as mentioned in the results section. When necessary, pUC18 was added to the transfection mixture to obtain a total of 10 mg of DNA. Cells were incubated with precipitate for 24 h, washed with phosphate buered saline (PBS), and stimulated for an additional 24 h when appropriate. Cells were collected in 200 ml reporter lysis buer (Promega) and subjected to the assays for luciferase and b-galactosidase as previously described (Brasier et al., 1989; Delegeane et al., 1987) . The data represent three independent experiments using dierent batches of DNA, and in each experiment transient transfections were performed in triplicate. Standard deviations were calculated using Sigmaplot (Jandel Corp.).
SDS ± polyacrylamide gel electrophoresis, Western blotting, and immunoprecipitations
A total of 1610 7 cells were lysed on ice in lysis buer (20 mM HEPES pH 7.4, 2 mM EGTA, 1 mM DTT, 1 mM Na 2 VO 3 (ortho), 1% Triton X-100, 10% glycerol, 10 mg/ml leupeptin, and 0.4 mM PMSF). Prior to SDS ± polyacrylamide gel electrophoresis and immunoprecipitations, protein concentrations were determined (Biorad), and equal amounts were used in the experiments. Whole-cell extracts were boiled for 5 min in the presence of Laemmli sample buer prior to separation on 12.5% SDS ± polyacrylamide gels. The proteins were transferred to a nitrocellulose ®lter (Millipore) in Tris-glycine buer using an electroblotter (Biorad). Membranes were blocked with PBS buer containing 5% non-fat milk prior to incubation with antibodies. Binding of each antibody was detected by chemiluminescence using ECL according to the manufacturer's recommendations (Amersham Corp.). For immunoprecipitations, whole cell lysates were incubated with anti-MEN2A-RET or anti-STAT3 antibodies, precipitated with Protein-A Sepharose beads (Pharmacia), and washed three times with lysis buer. The precipitates were boiled for 5 min in Laemmli sample buer and subjected to 12.5% SDS ± polyacrylamide gel electrophoresis.
Preparation of stable cell lines
Five hundred thousand NIH3T3 cells were plated in 100 mm dishes and transfected with 30 mg pCMV-MEN2A-RET and 20 mg pSV2-NEO. Control cell lines were generated by transfection with 30 mg pUC18 and 20 mg pSV2-NEO (NIH3T3 neo). After three cell replications, G418 was added in a concentration of 200 mg/ml. Transformants were selected and single cells cloned using the limiting dilution method. MEN2A-RET expressing clones were selected and then transfected with 20 mg pHYG and 30 mg pSG5-STAT3a or 30 mg pSG5-STAT3b, and after three cell replications hygromycin was added in a concentration of 250 mg/ml. Control cell lines were generated by transfection of a NIH3T3 (neo) cell line with 30 mg pUC18 and 20 mg pHYG (NIH3T3 neo/hyg). Double transformants were selected and STAT3a or STAT3b expressing clones were further subcultured and used in proliferation, reporter and soft agar assays.
Proliferation and soft agar assays
For proliferation assays, 2500 NIH3T3 (neo or neo/hyg), NIH3T3 (MEN2A-RET), NIH3T3 (MEN2A-RET/STAT3a), or NIH3T3 (MEN2A-RET/STAT3b) ®broblasts were cultured in 96-well plates and proliferation of each cell line was followed during 5 days using an MTC assay according to the manufacturer's recommendations (Promega). Colony formation assays were performed in 6-well dishes. Each well contained 1.5 ml of 0.7% agarose in DMEM as the bottom layer. The top layer consisted of 5000 NIH3T3 (neo/hyg), NIH3T3 (MEN2A-RET), NIH3T3 (MEN2A-RET/STAT3a), or NIH3T3 (MEN2A-RET/STAT3b) ®broblasts in 1.5 ml of 0.35% agarose in DMEM. After 3 weeks of incubation, colonies were stained with 0.05% Crystal Violet for 4 h and counted. Data represent three independent experiments, and each experiment was performed in triplicate. Representative images of colony formations were obtained using a Confocal Laser Scanning Microscope (Zeiss; 640).
